{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:15:15Z","timestamp":1791951315907,"version":"4.3.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:p>Background: Duchenne muscular dystrophy (DMD) exhibits substantial variability in rates of disease progression and response to treatment. This has hindered treatment development and complicated interpretation of drug effects in clinical trials. Objective: We hypothesized that a multivariate combination of early-age clinical outcome measurements can explain differential disease progression. Methods: Data on boys with DMD (ages 4\u2013&lt;10 years), both treated with steroidal anti-inflammatories and untreated, were obtained from CINRG Duchenne Natural History Study (n\u200a=\u200a209) and vamorolone VBP15-002\/003\/LTE (n\u200a=\u200a46) studies. Velocities from three timed function tests (TFTs; stand from supine, run\/walk 10 meters, and climb 4 stairs) were simultaneously modeled in a longitudinal latent class analysis. Results: Three classes of differentially progressing early age DMD motor trajectories were identified. Quicker decline\/progression was associated with lower baseline TFT velocities, earlier loss of ability to finish a TFT, and lower predicted velocities. Earlier substantial steroid exposure was associated with greater TFT velocities while the moderate progression class was observed to have the largest difference in performance between boys treated early with steroids vs. not. Sample size calculations with the class showing the largest treatment response showed a large reduction in required sample size as compared to using summaries from all participants. Gene mutations were also investigated in post-hoc analyses, with mutations near the beginning of the DMD gene (Dp427 absent and Dp140\/Dp71 present) found to be enriched in the slowest progressing class. Conclusions: This study provides insight into the variation in DMD progression through a latent class analysis. Our findings show class-related trajectories of motor outcomes and pharmacological response to corticosteroids, and suggest that enrichment strategies and\/or subgroup analyses could be considered further in design of therapeutic interventions in DMD.<\/jats:p>","DOI":"10.3233\/jnd-221527","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T11:53:23Z","timestamp":1676634803000},"page":"349-364","source":"Crossref","is-referenced-by-count":17,"title":["Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy"],"prefix":"10.1177","volume":"10","author":[{"given":"Yuan","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Boston University, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CINRG DNHS and Vamorolone 002\/003\/LTE Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[{"name":"University of California Davis School of Medicine, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula R.","family":"Clemens","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA"},{"name":"Department of Veteran Affairs Medical Center, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather-Dressman","family":"Gordish","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Children\u2019s National Health System, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Illei","sequence":"additional","affiliation":[{"name":"ReveraGen BioPharma, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"ReveraGen BioPharma, Rockville, MD, USA"},{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University\u2014SUNY, Binghamton, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh J.","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Carleton University, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"6","key":"10.3233\/JND-221527_ref1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"issue":"1","key":"10.3233\/JND-221527_ref2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1083\/jcb.201402079","article-title":"Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy","volume":"207","author":"Dadgar","year":"2014","journal-title":"J Cell Biol"},{"key":"10.3233\/JND-221527_ref3","doi-asserted-by":"crossref","unstructured":"Desguerre I , Christov C , Mayer M , Zeller R , Becane HM , Bastuji-Garin S , et al. Clinical heterogeneity of Duchenne muscular dystrophy (DMD): Definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS One. 2009;4(2). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0004347","DOI":"10.1371\/journal.pone.0004347"},{"issue":"4","key":"10.3233\/JND-221527_ref4","first-page":"179","article-title":"Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies","volume":"39","author":"Hoffman","year":"2020","journal-title":"Acta Myologica"},{"issue":"2","key":"10.3233\/JND-221527_ref5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejpn.2011.07.001","article-title":"Motor and respiratory heterogeneity in Duchenne patients: Implication for clinical trials","volume":"16","author":"Humbertclaude","year":"2012","journal-title":"European Journal of Paediatric Neurology"},{"issue":"5","key":"10.3233\/JND-221527_ref6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3233\/JND-210689","article-title":"A randomized, double-blind, placebo-controlled, global phase 3 study of edasalonexent in pediatric patients with Duchenne muscular dystrophy: Results of the PolarisDMD trial","volume":"8","author":"Finkel","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"10.3233\/JND-221527_ref7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: One gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.3233\/JND-221527_ref8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/jcm8050649","article-title":"The \u201cUsual Suspects\u201d: Genes for inflammation, fibrosis, regeneration, and muscle strength modify Duchenne muscular dystrophy","volume":"8","author":"Bello","year":"2019","journal-title":"J Clin Med"},{"issue":"3","key":"10.3233\/JND-221527_ref9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/WNL.0b013e318207afeb","article-title":"SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy","volume":"76","author":"Pegoraro","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.3233\/JND-221527_ref10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.23819","article-title":"LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy","volume":"73","author":"Flanigan","year":"2013","journal-title":"Ann Neurol"},{"issue":"10","key":"10.3233\/JND-221527_ref11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/jnnp-2014-308409","article-title":"Validation of genetic modifiers for Duchenne muscular dystrophy: A multicentre study assessing SPP1 and LTBP4 variants","volume":"86","author":"van den Bergen","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JND-221527_ref12","doi-asserted-by":"crossref","unstructured":"Bello L , Punetha J , Gordish-Dressman H , Giri M , Hoffman EP , Bello L , et al. Association study of exon variants in the NF-\u03baB and TGF\u03b2 Pathways identifies CD40 as a modifier of Duchenne muscular dystrophy. Am J Hum Genet 2016;99(5). https:\/\/doi.org\/10.1016\/j.ajhg.2016.08.023","DOI":"10.1016\/j.nmd.2016.06.049"},{"key":"10.3233\/JND-221527_ref13","doi-asserted-by":"crossref","first-page":"14143","DOI":"10.1038\/ncomms14143","article-title":"Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy","volume":"8","author":"Hogarth","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.3233\/JND-221527_ref14","doi-asserted-by":"crossref","first-page":"12167","DOI":"10.1038\/s41598-019-48548-9","article-title":"Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne muscular dystrophy","volume":"9","author":"Hathout","year":"2019","journal-title":"Sci Rep"},{"issue":"10119","key":"10.3233\/JND-221527_ref15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: A prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"The Lancet"},{"issue":"5","key":"10.3233\/JND-221527_ref16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","article-title":"Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy","volume":"26","author":"Mercuri","year":"2016","journal-title":"Jefferies JL, editor. Neuromuscul Disord"},{"issue":"9","key":"10.3233\/JND-221527_ref17","doi-asserted-by":"crossref","first-page":"e0221097","DOI":"10.1371\/journal.pone.0221097","article-title":"Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy","volume":"14","author":"Muntoni","year":"2019","journal-title":"PLoS One"},{"issue":"15","key":"10.3233\/JND-221527_ref18","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddaa132","article-title":"Serum biomarkers associated with baseline clinical severity in young steroid-na\u00efve Duchenne muscular dystrophy boys","volume":"29","author":"Dang","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JND-221527_ref20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","article-title":"Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug","volume":"136","author":"Conklin","year":"2018","journal-title":"Pharmacol Res"},{"issue":"13","key":"10.3233\/JND-221527_ref21","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"issue":"9","key":"10.3233\/JND-221527_ref22","doi-asserted-by":"crossref","first-page":"e1003222","DOI":"10.1371\/journal.pmed.1003222","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study","volume":"17","author":"Smith","year":"2020","journal-title":"PLoS Med"},{"issue":"1","key":"10.3233\/JND-221527_ref23","doi-asserted-by":"crossref","first-page":"e2144178","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: A 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"15","key":"10.3233\/JND-221527_ref25","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with duchenne muscular dystrophy: A randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.3233\/JND-221527_ref26","doi-asserted-by":"crossref","first-page":"465LP","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy","volume":"86","author":"Gloss","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JND-221527_ref27","doi-asserted-by":"crossref","unstructured":"Matthews E , Brassington R , Kuntzer T , Jichi F , Manzur AY Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews. 2016;(5). https:\/\/doi.org\/10.1002\/14651858.CD003725.pub4","DOI":"10.1002\/14651858.CD003725.pub4"},{"issue":"6","key":"10.3233\/JND-221527_ref28","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/mus.26441","article-title":"Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy","volume":"59","author":"Connolly","year":"2019","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.3233\/JND-221527_ref30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13023-021-02158-9","article-title":"Growth pattern trajectories in boys with Duchenne muscular dystrophy","volume":"17","author":"Stimpson","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.3233\/JND-221527_ref31","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/jcsm.12914","article-title":"Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy","volume":"13","author":"Chesshyre","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"10.3233\/JND-221527_ref32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v078.i02","article-title":"Estimation of extended mixed models using latent classes and latent processes: The R package lcmm","volume":"78","author":"Proust-Lima","year":"2017","journal-title":"J Stat Softw"},{"key":"10.3233\/JND-221527_ref33","doi-asserted-by":"crossref","unstructured":"Wickham H ggplot2: Elegant graphics for data analysis. Springer-Verlag New York. Springer; 2016. https:\/\/doi.org\/10.1007\/978-0-387-98141-3","DOI":"10.1007\/978-0-387-98141-3"},{"issue":"3","key":"10.3233\/JND-221527_ref35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/psp4.12753","article-title":"Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy","volume":"11","author":"Lingineni","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10101","key":"10.3233\/JND-221527_ref37","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"The Lancet"},{"issue":"14","key":"10.3233\/JND-221527_ref38","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2217\/cer-2020-0095","article-title":"Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy","volume":"9","author":"Campbell","year":"2020","journal-title":"J Comp Eff Res"},{"issue":"1","key":"10.3233\/JND-221527_ref39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","article-title":"A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy","volume":"28","author":"Goemans","year":"2018","journal-title":"Neuromuscular Disorders"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-221527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:52:23Z","timestamp":1777506743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-221527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":34,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jnd-221527","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}